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Abstract
Background: Lung cancer is the most lethal cancer and almost 90% of lung cancer is due to cigarette smoking.
Even though nicotine, one of the major ingredients of cigarette smoke and the causative agent for addiction, is
not a carcinogen by itself, several investigators have shown that nicotine can induce cell proliferation and
angiogenesis. We observed that the proliferative index of nicotine is different in the lung cancer cell lines H1299
(p53-/-) and A549 (p53+/+) which indicates that the mode of up-regulation of survival signals by nicotine might be
different in cells with and without p53.
Results: While low concentrations of nicotine induced activation of NF-B, Akt, Bcl2, MAPKs, AP1 and IAPs in
H1299, it failed to induce NF-B in A549, and compared to H1299, almost 100 times higher concentration of
nicotine was required to induce all other survival signals in A549. Transfection of WT-p53 and DN-p53 in H1299
and A549 respectively, reversed the mode of activation of survival signals. Curcumin down-regulated all the survival
signals induced by nicotine in both the cells, irrespective of their p53 status. The hypothesis was confirmed when
lower concentrations of nicotine induced NF-B in two more lung cancer cells, Hop-92 and NCI-H522 with mutant
p53 status. Silencing of p53 in A549 using siRNA made the cells susceptible to nicotine-induced NF-B nuclear
translocation as in A549 DN-p53 cells.
Conclusions: The present study reveals a detrimental role of nicotine especially in lung cancer patients with
impaired p53 status and identifies curcumin as a potential chemopreventive.
Background
Lung cancer is the most lethal of all cancers worldwide
with a dismal prognosis and 5 year survival rate of <
15%. Reports indicate that p53 alterations are the most
common genetic events in lung cancer development and
50-60% of non-small cell lung cancers (NSCLC) and
90% of small cell lung cancers (SCLC) contain p53
mutations [1]. The major reason for lung cancer inci-
dence is tobacco smoke, which contains nicotine. There
is no evidence indicating that nicotine is a carcinogen
by itself [2]; nevertheless, it has been demonstrated that
nicotine promotes the growth of cancer cell populations
in the lungs [3] by stimulating cell proliferation and
angiogenesis [4,5]. Chronic exposure to nicotine causes
mitogenic stimulus and leads to the activation of
growth-promoting and antiapoptotic signaling pathways
such as PI3K-Akt/mTOR, NF-B, COX-2, Bcl2, MAPKs
etc [6-10]. It has also been shown to induce secretion of
several growth factors and upregulate the calpain family
of proteins in lung cancer cells leading to the activation
of Raf/MAPK/ERK pathway [11-13]. Moreover, reports
indicate that nicotine inhibits apoptosis induced by var-
ious stimuli including chemotherapeutic agents in lung
cancer cells where survivin and XIAP are suggested to
play a key role [14].
Curcumin, a polyphenol isolated from Curcuma longa,
has been extensively investigated for its cancer chemo-
preventive and chemotherapeutic properties, which are
attributed mainly to its antioxidant and anti-inflamma-
tory potential [15,16]. Curcumin, with its potent anti-
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inflammatory property, is expected to exert chemopre-
ventive effects on carcinogenesis and has been shown to
modulate numerous transcription factors, protein
kinases etc. that have been linked to the pathophysiol-
ogy of cancer [17]. It up-regulates several apoptosis
inducing genes such as p53 and p21 [17] and down-reg-
ulates pro-survival genes such as NF-B, Akt, Bcl2 and
Cyclin D1 [17,18] induced by various stimulants. This
has been suggested to be the reason for its chemosensi-
tizing efficacy [17,19]. Despite the bioavailability of cur-
cumin being very low, studies indicate that even at a
physiologically achievable concentration, curcumin is
sufficient for its chemopreventive and chemotherapeutic
activity [20].
p53, which regulates many cellular activities including
cell cycle arrest and apoptosis, is the most commonly
mutated gene in human cancers [21]. It has been well
documented that absence of functional p53 in cells ren-
der them resistant to chemotherapy, and restoration of
p53 lessen the tumor occurrence [22]. One major func-
tion of p53 is to control DNA replication by inducing
p21 protein, which promotes cell cycle arrest by modify-
ing the phosphorylation of the cyclin-dependent kinases
[23], although regulation of p21 expression independent
of p53 also has been reported [24]. Activation of the
p53-p21 pathway and induction of both p53 and p21
are often reported in response to DNA damaging agents
including nicotine [25].
The nuclear transcription factor NF-B is an impor-
tant survival signal which induces the expressions of
diverse target genes including COX-2, Cyclin D1 and
XIAP that promote cell proliferation, regulate apoptosis
and stimulate invasion and metastasis [9,26]. Studies
indicate that simultaneous inhibition of p53 and NF-B
transcriptional activities decide the fate of the cell
[27,28]. Previous studies have also demonstrated that
nicotine activates signal transduction pathways relevant
to carcinogenesis through the activations of MAPK and
PI3-K/Akt pathways [6,7].
In the present study we have tried to correlate the
effect of nicotine to the p53 status of lung cancer cells,
especially NSCLC cell lines of adenocarcinoma or large
cell carcinoma origin. We selected these cells for our
study because cigarette smoking is a major risk factor in
the development of NSCLC, which accounts for 80% of
all lung cancers [14]. We report in this study that the
induction of survival signals in lung cancer cells by nico-
tine is dependent on the p53 status of the cells and iden-
tify p53 status as an important predictor of lung cancer
progression. Additionally, we have attempted in delineat-
ing the signaling cross-talk mechanism orchestrating
p53-dependent regulation and expression of survival sig-
nals such as NF-B, AP-1, Akt, Bcl2 etc., in the presence
and absence of p53 expression. Our findings underscore
that p53 plays an essential role in regulating survival sig-
nals, especially NF-B, in response to nicotine. We also
present data supporting our contention that curcumin
down-regulates all the survival signals induced by nico-
tine, independent of the p53 status of the cell.
Results
Nicotine induces more proliferation in lung cancer cells
lacking p53, which is down-regulated by curcumin
Even though nicotine-induced proliferation of lung can-
cer cells has been reported [4], our findings show for
the first time that, among the lung cancer cell lines,
nicotine induces more proliferation in H1299 lacking
p53 especially at lower concentrations (10-9M -10-7M)
than A549 with active p53 (maximum at 10-7M -10-6M).
Of interest, pre-treatment with a non-toxic concentra-
tion of curcumin significantly reduced (p < 0.001) the
viability of both lung cancer cells (Fig 1. A-B).
Nicotine induces NF-B in H1299 cells but not in A549
cells
Nicotine has been shown to activate NF-B in cancer
cells of various origins, including lung [3,8]. We also
have reported earlier that cigarette smoke induces
strong activation of NF-B in H1299 cells [29]. In the
present study, H1299 and A549 cells were exposed to
various concentrations of nicotine and the status of
nuclear translocation of NF-B was studied. Interest-
ingly, nicotine could activate NF-B only in H1299 cells
(Fig. 2A) while it failed to induce a significant activation
of NF-B in A549 cells at any of the concentrations stu-
died (Fig. 2B). In H1299 cells, lower concentrations (10-
9M-10-7M) of nicotine induced maximum activation of
NF-B and a time kinetics study using 10-8 M nicotine
showed maximum activation at 30 min of exposure to
nicotine (Fig. 2C). In congruence, the phosphorylation
pattern of IKK and degradation pattern of IBa (Fig.
2D) correlated with that of the NF-B activation, attest-
ing that nicotine induces NF-B through the classic
pathway. The specificity of the NF-B band was verified
by super shift assay and by cold competition (Fig. 2E).
The activation of NF-B induced by nicotine in H1299
cells was completely abolished by treatment with 10 μM
curcumin (Fig. 2F).
Nicotine-induced phosphorylation of Akt and over
expression of COX-2 and Cyclin D1 in lung cancer cells
are inhibited by curcumin
We compared the effect of nicotine in A549 and H1299
cells in inducing pro-survival molecular entities-Akt,
COX-2 and Cyclin D1, which generally get activated in
response to NF-B activation. Though nicotine was inef-
fective in inducing NF-B in A549 cells, it effectively
induced Akt, COX-2 and Cyclin D1 in both the cells
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(Fig. 3A-C) indicating that nicotine activates these pro-
survival signaling molecules independent of NF-B.
However, there was a marked difference in the expres-
sion pattern of all these survival signals between the
investigated cell lines. It was noticed that, while nicotine
induces activation of these survival molecules in the
range of 10-9M - 10-7M in H1299 cells, a 10-100 fold
high concentration of nicotine was needed to induce the
same effect in A549 (Fig. 3A-C). Despite studies report-
ing the interdependence and cross-talk between Akt and
NF-B [26], phosphorylation of Akt by PI3K pathway
independent of NF-B is also well evidenced [30-33].
Similarly, while several reports strongly correlate the
involvement of NF-B in Cyclin D1 regulation [30],
there are reports which clearly demonstrate the tran-
scription of Cyclin D1, independent of NF-B, in cell
lines including A549 [32,4]. The protein level expression
of Cyclin D1 in A549 was low compared to that in
H1299 cells at all the concentrations studied (Fig. 3C).
We infer from these results that nicotine-induced
expression of these survival signals was severely com-
promised in the presence of curcumin in both the inves-
tigated cell lines (Fig. 3D-F) and hence we draw
attention to the protective role of curcumin against sur-
vival and proliferative signals induced by nicotine.
Curcumin prevents the over-expression of IAPs and Bcl2
by nicotine
The IAP family of proteins involved in apoptosis regulation
is generally activated in response to NF-B activation [33].
Consistent with previous reports indicating that 1 μM
nicotine induces the IAP family members, XIAP and survi-
vin [14], we also observed the over-expression of XIAP and
survivin in A549 and H1299 cell lines, albeit difference in
the concentration of nicotine for effective stimulation of
these proteins. However, we observed robust expression of
cIAP-1 too in both the cell lines by nicotine (Fig. 4A-C),
though Dasgupta et al [14] did not observe it in A549 cells.
It was inferred that while nicotine induces activation of
these survival signals in the range 10-9 M-10-7 M in H1299
cells, it induces the same level of activation in A549 cells at
10-6 M-10-4 M range (Fig. 4A-C). Additionally, because
Bcl2 is considered as a general inhibitor of apoptosis, we
evaluated the role of nicotine in its induction above basal
level and tested the effect of curcumin in conferring che-
moprotection. As in the case of other survival signals, a 10-
100 fold higher concentration of nicotine was necessary to
induce Bcl2 in A549 cells, compared to H1299 cells (Fig.
4D) although, curcumin abolished it more or less comple-
tely in both the cell lines. Results obtained thus far indicate
that in the investigated lung cancer cell lines, curcumin
Figure 1 Nicotine induces more proliferation in H1299 than in A549, which is down regulated by curcumin. (A-B) The cells were treated
with nicotine and/or curcumin for 72 h and 24 h respectively for MTT assay and thymidine incorporation assay. Tritiated thymidine (0.5 μCi/well)
was added 6 h before the completion of incubation. All error bars indicate standard deviation between three independent experiments.
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completely inhibits the over-expression of these survival
signals (Fig. 4E-H) independent of the p53 status and the
concentration of nicotine, strongly suggesting a preventive
action of curcumin against nicotine-induced promotion
and progression of lung cancer through up-regulation of
antiapoptotic molecules.
Nicotine-induced phosphorylation of MAPKs and nuclear
translocation of AP-1 in lung cancer cells are down-
regulated by curcumin
Over-expression of cyclin D1 and IAPs by nicotine even
in the absence of NF-B led us to speculate the involve-
ment of other pathways regulating the expression of
these proteins. Involvement of the MAPK pathway [7]
and the induction of cyclin D1 through the MAPK-AP-
1 pathway [34] in nicotine-induced cell signaling is well
evidenced. Induction of IAPs by MAPKs independent of
NF-B has also been reported [35]. We therefore per-
formed a time kinetic study up to 120 min to investigate
the functional role of MAPK in H1299 and A549 cells,
by analyzing their phosphorylation status in the pre-
sence of nicotine and found that, nicotine induces maxi-
mum phosphorylation of all the MAPKs at 30 min (data
not shown). Dose response study revealed that all the
three MAPKs are phosphorylated in both the cell lines,
being maximally activated at 10-8M concentration of
Figure 2 Nicotine activates NF-B in H1299, but not in A549. (A-B) Nuclear extracts were prepared from the cells treated with indicated
concentrations of nicotine for 30 min and NF-B nuclear translocation was assessed by EMSA. (C) H1299 cells were treated with 10-8 M nicotine
for different time intervals and EMSA was done. (D) The cytosolic extracts of the time kinetic study of NF-B activation were Western blotted
against the respective antibodies. (E) The nuclear extract of nicotine-treated H1299 cells were incubated with p50 and p65 antibodies or
unlabelled oligo and EMSA was conducted to detect supershift and cold competition respectively. (F) H1299 cells were treated with curcumin
and then with nicotine for 30 min and EMSA was done. All blots and EMSAs are representative samples of three independent experiments.
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nicotine in H1299 cells (Fig. 5A) and at 10-6 M in A549
cells (Fig. 5B). However, curcumin treatment (10 μM)
inhibited the phosphorylation of these MAPKs by nico-
tine in both the cells (Fig. 5C-D).
Regulation of MAPK pathway by nicotine through p53
has already been reported [25,36]. We therefore assessed
whether p53 has any regulatory role in the activation of
AP-1, which gets translocated to the nucleus in response
to the phosphorylation of MAPKs since, up-regulation
of AP-1 activity by nicotine has been reported in the lit-
erature [37]. Interestingly, though nicotine failed to acti-
vate NF-B in A549 cells, it activated AP-1 very
efficiently in both H1299 and A549 cells (Fig. 5E-F)
though the pattern of nuclear translocation of AP-1 was
in parallel with the phosphorylation pattern of MAPKs
in the respective cell lines. As in the case of MAPKs,
Figure 3 Curcumin inhibits nicotine-induced phosphorylation of Akt and over expression of COX-2 and Cyclin D1. (A-C) The cells were
treated with various concentrations of nicotine (30 min for phospho-Akt and 24 h for COX-2 and Cyclin-D1) and whole cell lysates prepared
were blotted against phospho-Akt, COX-2 and Cyclin-D1 antibodies. (D-F) The cells were treated with curcumin and then with nicotine (10-8 M
in H1299 and 10-6 M in A549) and whole cell lysates were blotted as in (A-C). All blots are representative samples of three independent
experiments.
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curcumin treatment down regulated this activation
almost completely in both the cells (Fig. 5G-H).
Introduction and inactivation of p53 in H1299 and A549
cells respectively, bring about reciprocal effect on the
activation pattern of NF-B, MAPKs and AP-1 in both the
cells
The correlation between NF-B nuclear translocation
and the p53 status of cells is controversial. Some
researchers contend that p53 is needed for NF-B acti-
vation [38,39] while, others have shown that activation
of NF-B can be induced in a p53 independent manner
[40]. We noticed differences in the activation pattern of
NF-B, MAPKs and AP-1 in cells harboring p53 versus
cells lacking p53. To corroborate whether this distinc-
tion is due to the p53 status of the cells, we transfected
H1299 cells with p53 WT plasmid and A549 cells with
p53 DN plasmids, followed by selection of the clones
Figure 4 Nicotine-induced over expression of IAPs and Bcl2 is inhibited by curcumin. (A-D) The cells were treated with nicotine for 24 h
and whole cell lysates were Western blotted using antibodies against XIAP, cIAP-1 survivin and Bcl2. (E-H) The cells were treated with curcumin
and then with nicotine (10-8M for H1299 and 10-6 M for A549) and whole cell lysates were blotted as in (A-D). All blots are representative
samples of three independent experiments.
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Figure 5 Curcumin downregulates nicotine-induced phosphorylation of MAPKs and nuclear translocation of AP-1. (A-B) The cells were
treated with nicotine (10-9-10-2M) for 30 min and whole cell lysates were blotted against respective phospho specific antibodies. (C-D) The cells
were treated with curcumin and then with nicotine (10-8M for H1299 and 10-6 M for A549) and whole cell lysates were blotted as in (A-B). (E-F)
Nuclear extracts were prepared from the cells treated with nicotine (10-9-10-2M) for 30 min. and AP-1 activation was assessed by EMSA. Super
shift and cold competition was done by incubating the nuclear extract with c-jun antibody and unlabelled oligo respectively. (G-H) The cells
were treated with curcumin and then with nicotine (10-8M for H1299 and 10-6 M for A549) and EMSA was done using nuclear extracts. All blots
and EMSAs are representative samples of three independent experiments.
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with maximum p53 expression for further studies. In
H1299-p53 WT, clone 6 (Fig. 6A) and in A549-p53 DN,
clone 3 was selected (Fig. 6B). Whereas nicotine failed
to induce NF-B nuclear translocation in A549 cells, it
caused significant induction of NF-B in A549-p53 DN
cells within the concentration range of 10-9M - 10-7M
similar to H1299 cells (Fig. 6C). Supporting this obser-
vation, inhibition of p53 in A549 cells using 40 μM pifi-
thrin-a, which completely inhibits p53 (Fig. 6E) induced
NF-B nuclear translocation in A549 cells (Fig. 6F).
Likewise, nicotine failed to induce NF-B activation in
H1299-p53 WT cells except at a very high concentra-
tion of 10-2 M (Fig. 6D) though, it induced very strong
activation of NF-B in H1299 cells at 10-9-10-7 M. This
confirms the interdependence between NF-B and p53.
Furthermore, the mode of phosphorylation of MAPKs
and the nuclear translocation of AP-1 by nicotine was
also seen to be reversed in the transfected cells
(Fig. 6G-J), further adding support to our hypothesis.
Proliferative as well as clonogenic potential induced by
nicotine may be regulated through up-regulation of p53
and p21, and is down-regulated by curcumin
Because of the difference in the p53 status between the
investigated cells, we studied whether p53 can differen-
tially regulate the clonogenicity by nicotine in these
cells. While 10-8M nicotine induced maximum number
of clones in H1299 cells, 10-6M nicotine produced maxi-
mum proliferation in A549 cells as indicated by the big-
ger size of the colonies formed (Fig. 7A-B). Moreover,
the number and size of the clones was much higher in
H1299 cells compared to A549. As expected, the num-
ber of clones by nicotine addition in A549 was escalated
when p53 was shut down, whereas those produced in
H1299 was significantly reduced (p < 0.005) when p53
was transfected (Fig. 7A-B). However, in both the cells,
pretreatment with curcumin (10 μM, 2 h) drastically
reduced the number and size of the clones induced by
nicotine, clearly indicating that curcumin negatively reg-
ulates clonogenicity (Fig. 7A-B).
As part of investigation of this difference in the activa-
tion pattern of various survival signals by nicotine in
cells with and without p53, we evaluated the effect of
nicotine on expression levels of p53 and p21 in A549
parental and A549-p53 DN cells. Interestingly, while
lower concentrations (10-9 M - 10-7 M) of nicotine
induced over-expression of p53 and p21 in A549 cells, it
failed to induce significant changes in the expression
pattern of p53 and p21 in A549-p53 DN cells (Fig. 7C-
D). To check whether p53 is the only molecule regulat-
ing the p21 signaling in A549 cells, we also investigated
the expression status of p21 in response to nicotine in
H1299 cells. We did not find any significant difference
in the expression of p21 in H1299 cells (Fig. 7E),
implying that p53 is the key regulator of p21 in nico-
tine-induced signaling events. To confirm this hypoth-
esis, we checked the p21 status in H1299-p53 WT cells
in response to nicotine. As in the case of A549 cells, a
strong induction of p53 was produced by nicotine in
these cells (Fig. 7E) which confirms the regulatory role
of p53 in nicotine-induced p21 expression.
Loss of function of p53 enhances nicotine-induced
proliferation and NF-B nuclear translocation in lung
cancer cells
We further validated our hypothesis that impaired p53
status leads to proliferation and induction of survival
signals in lung cancer cells, by treating two other lung
cancer cells harboring mutant p53(Hop-92 and NCI-
H522) with nicotine and curcumin. We observed a sig-
nificant proliferation of these cells by lower concentra-
tions of nicotine (p < 0.001) which is prevented by
curcumin pre-treatment (Fig. 8A-B). As in H1299, nico-
tine induced NF-B nuclear translocation in these cells
too (Fig. 8C-D). Moreover, as we observed in A549-p53
DN cells, nicotine induced NF-B nuclear translocation
when p53 was silenced in A549 cells transfected with
p53 siRNA and interestingly, co-transfection of these
cells with WT p53 completely inhibited the nuclear
translocation of NF-B (Fig. 8E-F) confirming the role
of p53 in regulating nicotine-induced cell signaling.
Discussion
Enormous efforts have been devoted by various research
groups to identify the role of nicotine in the process of
carcinogenesis by tobacco. It has been implicated as a
potential risk factor in the proliferation of various can-
cer cells [14,41] and has been shown to induce
enhanced tissue perfusion and angiogenesis [5,42]. In
the present study, we have convincingly shown that
nicotine induces proliferation in lung cancer cells, espe-
cially in those with impaired p53 status. It also induces
an array of antiapoptotic factors in these cells. Although
nicotine has been shown to induce proliferation in lung
cancer cells [4], the regulatory role of p53 on nicotine-
induced proliferation has not yet been addressed. We
observed a significant increase in the proliferation of
lung cancer cells lacking p53. This established a ground
for us to evaluate the effect of p53 in the induction of
various survival signals by nicotine.
The relation between NF-B and p53 is controversial.
Conceptually, over-expression of NF-B is linked to the
development and progression of various tumors [43]
and inhibition of NF-B function allegedly suppress
tumorigenesis and leads to the regression of tumors. It
has been documented that both NF-B and p53 com-
pete for the transcriptional co-activators [28]. Recent
reports suggest that the presence of p53 prevents NF-B
Puliyappadamba et al. Molecular Cancer 2010, 9:220
http://www.molecular-cancer.com/content/9/1/220
Page 8 of 15
activation though, the mechanism is not clear. However,
contradicting these observations, p53-induced NF-B
activation has also been reported [44]. It has also been
shown that inhibition of p53 does not inhibit NF-B
function [27].
In our present study we observed a strong activation
of NF-B by nicotine in the p53 null H1299 cell line,
while no significant activation of the same was noted in
the p53 proficient A549 cells, at any of the concentra-
tions studied. Zhang et al [7] have reported that
Figure 6 Over-expression and silencing of p53 produce reciprocal effect on the activation pattern of NF-B, MAPKs and AP-1. (A-B)
H1299 and A549 cells were transfected with pcDNA3-p53 WT and pcDNA3-p53 DN constructs respectively and the stable clones selected were
lysed and Western blotted against p53 antibody. (C-D) H1299-p53 WT and A549-p53 DN cells were treated with nicotine (10-9-10-2M) for 30 min,
and EMSA was done using nuclear extracts. (E) A549 cells were treated with different concentrations of pifithrin-a (10-50 μM) for 4 h and the
whole cell lyasates prepared were Western blotted against p53 antibody. (F) A549 cells were treated with 40 μM pifithrin-a for 4 h followed by
nicotine (10-9-10-2M) for 30 min and EMSA was done. (G-H) H1299-p53 WT and A549-p53 DN cells were treated with nicotine (10-9-10-2M) for 30
min, and EMSA was done. (I-J) H1299 WT-p53 and A549 DN-p53 cells were treated with nicotine (10-9-10-2M) for 30 min and whole cell lysates
were Western blotted against respective phospho specific antibodies. All blots and EMSAs are representative samples of three independent
experiments.
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pre-treatment with 100 μM nicotine up-regulate both
mRNA and protein level expression of NF-B in A549.
However, supporting our observation, Moodie et al [45]
have reported that cigarette smoke condensate, in which
nicotine is one of the major components (0.3 mg/cigar-
ette), failed to induce NF-B in A549 cells.
A cross-talk between Akt and p53 acting as cell control
machinery for switching between survival and death has
been reported. Akt activation has also been reported in
p53 null cells [27]. In our study, 10-9M - 10-8M nicotine
induced phosphorylation of Akt in H1299 cells. In con-
trast, a 100 fold higher concentration of nicotine was
required to produce similar effects in A549. Several
reports indicate interdependence between NF-B and
Akt [26]. However, Akt independent activation of NF-B
has also been reported [30]. In the present study we
noted a strong phosphorylation of Akt by nicotine in
A549 cells, although it failed to induce NF-B in A549.
This indicates that, nicotine-induced Akt phosphoryla-
tion is independent of NF-B activation status of the cell.
Figure 7 Curcumin inhibits enhancement of clonogenicity by nicotine, which induces p53 and p21 in A549 and p21 in H1299-p53 WT.
(A-B) The cells were treated with nicotine and/or curcumin for 72 h, after which cells were split and seeded in six well plates, kept for 2 weeks
and clones developed were stained and counted. (C-E) The cells were treated with nicotine (10-9-10-2M) for 24 h and whole cell lysates were
Western blotted against p53 antibody. All figures are representative samples of three independent experiments.
Puliyappadamba et al. Molecular Cancer 2010, 9:220
http://www.molecular-cancer.com/content/9/1/220
Page 10 of 15
No clear consensus between p53 and COX-2 exists in
the literature. While some studies show that p53 up-reg-
ulates COX-2 [46], others show that p53 down-regulates
it [47]. We observed induction of COX-2 by nicotine in
A549 cells though it failed to induce NF-B, strengthen-
ing the notion that nicotine-induced COX-2 activation
in A549 cells is independent of NF-B. Even though
COX-2 is generally considered as an NF-B dependent
gene [26], there are studies which report the activation
of COX-2 independent of NF-B [48]. In parallel, we
observed an NF-B and p53 independent induction of
Cyclin D1 by nicotine, though the expression profile
Figure 8 Nicotine induces proliferation and NF-B nuclear translocation in Hop-92, NCI-H522 and p53-silenced A549 cells. (A-B) The
cells were treated with nicotine and/or curcumin and cell viability was measured by MTT assay. All error bars indicate standard deviation
between three independent experiments. (C-D) Nuclear extracts were prepared from the cells treated with indicated concentrations of nicotine
for 30 min and NF-B nuclear translocation was assessed by EMSA. (E) A549 cells were transfected with indicated concentrations of control-si
RNA or p53-si RNA and after 48 h, the whole cell lysates were Western blotted against p53 antibody. (F) A549 cells were transfected with
indicated concentrations of control-si RNA or p53-si RNA and after 48 h, treated with indicated concentrations of nicotine for 30 min and NF-B
nuclear translocation was assessed by EMSA. All blots and EMSAs are representative samples of three independent experiments.
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was less in A549 cells. Cyclin D1 is also considered as
an NF-B dependent gene [49] although, recent studies
implicate Cyclin D1 expression through pathways inde-
pendent of NF-B [32].
IAP family of proteins is another essential target of
NF-B [50]. The present study as well as a previous
study by Dasgupta et al [14], have noticed over-expres-
sion of IAPs by nicotine in A549 and H1299 cells. Of
interest, this is the first study reporting the difference in
the activation pattern of IAPs between both these cell
lines. Bcl2 is another molecule which has a key role in
regulating nicotine-induced survival signaling and has
often been considered as NF-B dependent. Interest-
ingly, we observed Bcl2 up-regulation in both the cell
lines, though the pattern of up-regulation varied
between cell lines. In rapport to our observation, a
novel nicotine-stimulated survival pathway that involves
Bcl2 phosphorylation through MAPK pathway has been
reported earlier [10].
Nicotine also induces p53 [25] which, often regulates
the phosphorylation pattern of MAPKs [36,51]. On the
contrary, another study reports that MAPK activation
occurs only in cells with functional p53 [52], indicating a
reciprocal interaction between p53 signaling pathway and
MAPK pathway. We observed a discrete difference in the
phosphorylation pattern of MAPKs in both the cells. The
involvement of p53 was further confirmed when the
phosphorylation pattern was reversed when p53 was
inactivated in A549 and introduced in H1299 cells.
AP-1 is a transcriptional regulator and phosphorylation
of MAPKs leads to nuclear translocation of AP-1 [53].
Although NF-B and AP-1 are regulated by different
mechanisms, several studies indicate that they are acti-
vated simultaneously [54]. Nicotine induced nuclear
translocation of AP-1 in both the cell lines, even though
it failed to induce NF-B in A549. However, as in the
case of MAPKs, depending on the p53 status of the cell
line, there was a significant change in the activation pat-
tern of AP-1. In support of the involvement of p53 in
AP1 activation, the nuclear translocation pattern of AP-1
was reversed in A549-p53DN and H1299-p53WT cells.
The ability of nicotine to enhance adherence-indepen-
dent proliferation of tumor cells is well documented
[55]. We observed a marked difference in the number
and size of the clones between both H1299 and A549
cells treated with nicotine, which was strongly corrobor-
ating within the concentration range of nicotine at
which the survival signals are activated in both the cells,
implicating a regulatory role of these survival signals on
nicotine-induced enhancement of clonogenic potential.
As there was a drastic reduction in the number of
clones on treatment with curcumin in both the cells, it
is also evident that curcumin inhibits the effect of nico-
tine by down-regulating these survival signals. Nicotine
has a high toxicity in comparison to many other alka-
loids such as cocaine and higher doses of nicotine have
been reported to be lethal (0.5-1.0 mg/kg for adult
humans, and 10 mg for children) [56]. In our study, we
also observed that all the survival signals induced by
nicotine are abrogated at higher concentrations suggest-
ing that there may be a balance between the pro-survi-
val and anti-survival signals induced by this compound
at different concentrations. However the exact concen-
tration at which this switching over occurs is still
unclear as we observed the cessation of various survival
signals at different concentrations of nicotine.
Activation of almost all the survival signals investi-
gated in this study is involved in the process of lung
cancer progression. It has also been shown that p53 and
p21 negatively regulate these survival signals [28,47,23].
Induction of p53 and its downstream target p21 by
nicotine has been correlated to the inhibition of cell
proliferation by nicotine [25]. We observed a strong
induction of p53 as well as p21 by lower concentrations
of nicotine in A549 cells which may be the reason for
the absence of proliferative signals at this concentration
in these cells. A strong induction of p21 was noted in
response to nicotine in H1299 cells transfected with
wild type p53 as well. But we did not observe any
change in the expression of p53 in A549-p53DN cells.
This is expected since p53 is non-functional in these
cells, and hence cannot regulate the expression of p21.
Similarly, no difference in expression of p21 in response
to nicotine treatment was noted in H1299 cells as well
as A549-p53DN cells, again confirming the role of p53
in regulating the nicotine-induced signaling events.
Hence, we hypothesize that the induction of p53 and
p21 by lower concentrations of nicotine in A549 cells
may be one of the reasons why nicotine failed to induce
these survival signals at these concentrations in A549,
though further studies are required to confirm this
hypothesis.
Our hypothesis that p53 is the key regulator of nico-
tine-induced survival signaling in lung cancer cells, was
further authenticated in two more lung cancer cells with
mutant p53 status. Lower concentrations of nicotine
induced proliferation in these cells and pre-treatment
with curcumin prevented it and, as in H1299, lower
concentrations of nicotine induced NF-B nuclear trans-
location in these cells too. In addition, when p53 was
silenced in A549 cells by p53 siRNA, as in A549-p53
DN cells, nicotine induced a strong nuclear transloca-
tion of NF-B, while co-transfection of these cells with
WT p53 completely inhibited the same, substantiating
the regulatory role of p53 in nicotine signaling.
The data obtained from our study is very significant
because the average plasma level concentration of nico-
tine in a typical pack per day smoker is between 20-40
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mg [57]. Studies have indicated that chemotherapeutic
drugs like cisplatin, which induce p53 in cells with a
wild-type p53 gene can induce apoptosis in these cells
while cells with mutated p53 are unaffected [58]. Sup-
porting this observation, Dasgupta et al [14] have shown
that nicotine prevents the cisplatin-induced apoptosis in
A549 cells with active p53. We also disclose a detrimen-
tal role of nicotine in lung cancer patients with mutant
p53 status. Hence our study has proved beyond doubt
that p53 has a significant role in regulating the survival
signals induced by nicotine in lung cancer cells. It is
also clear that curcumin down-regulates these survival
signals induced by nicotine in both the cells, indepen-
dent of their p53 status.
Conclusions
Our study identifies nicotine as a potential tumor pro-
moter, especially in people with impaired p53 status and
illustrates a chemopreventive role to curcumin against
nicotine-induced lung cancer progression.
Methods
Cell lines
H1299 cell line was a gift from Prof. BB Aggarwal, MD
Anderson, Houston, A549 and NCI-H522 cells were
procured from NCCS, Pune, and Hop-92 was obtained
from NCI, Bethesda, MD.
Chemicals
Antibodies against p53, IBa, XIAP and cIAP-1 and
phosphospecific antibodies against-IKK, p38, Akt and
p42/44 were purchased from Cell Signalling (Beverly,
MA) and those against p50, RelA, pJNK, COX-2 and
Survivin were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). G418 and pifithrin-a were procured
from Calbiochem (San Diego, USA). Lipofectamine was
procured from Invitrogen (Carlsbad, CA) and control
siRNA and p53 siRNA were procured from Dharmacon,
Inc (Chicago, IL). All other chemicals were purchased
from Sigma Chemicals (St. Louis, MO).
Mode of treatment
In all combination treatments 10 μM curcumin was
added 2 h before nicotine (10-8 M in H1299 and 10-6 M
in A549).
MTT Assay
Proliferative/cytotoxic effect of nicotine and/or curcumin
was determined by MTT assay as described earlier [18].
[3H] Thymidine incorporation
For [3H] thymidine incorporation assay, cells were
seeded in 96 well plates and treated with required con-
centrations of the drugs. After 18 h of incubation, [3H]
thymidine was added (0.5 μCi/well) and further incu-
bated for 6 h. Then the culture medium was removed,
the cells were washed twice with phosphate-buffered sal-
ine (PBS), treated with 5% trichloroacetic acid, pelleted
and supernatant was removed. Cells were then washed
with ethanol and solubilized with 0.2N NaOH, contents
of each well were mixed with 3 ml scintillation fluid and
the radioactivity was counted using a liquid scintillation
counter [59]. The experiment was repeated thrice and
the error bars indicate standard deviation.
Electrophoretic Mobility Shift Assay (EMSA)
To detect activation of NF-B and AP-1, EMSA was
done and visualized by a Phosphor Imager (Bio-Rad Per-
sonal FX). The specificity of the bands were confirmed
by super shift [29].
Isolation of Plasmids
The plasmids were isolated by the standard alkaline lysis
method [60].
Stable Transfection
H1299 Cells were transfected with pcDNA3-p53WT or
the empty vector pcDNA3 while A549 cells were trans-
fected with pcDNA3-p53 DN or the empty vector
pcDNA3 using the calcium-phosphate transfection kit
(Life Technologies, Inc.) according to manufacturer’s
protocol and selected using G418 (150 μg/ml) [61].
siRNA Transfection
A549 cells were transiently transfected with control
siRNA, p53 siRNA and/or WT-p53 plasmid using lipo-
fectamine 2000 reagent according to manufactures pro-
tocol (Invitrogen).
Western blot
The total protein after treatment with nicotine and/or
curcumin was electroblotted as described earlier [18]
and developed by Enhanced Chemiluminescence
(Immobilon Western, Miliipore, Billerica, MA).
Clonogenic assay
The cells were treated with nicotine and/or curcumin
for 72 h, as in MTT assay after which the cells were
split and seeded in six well plates and clonogenic assay
was done as described by Franken et al [62].
Statistical analysis
Statistical significance was calculated using one-way
ANOVA followed by Tukey post-hoc analysis.
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